{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:13:42Z","timestamp":1789398822902,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ibrutinib has made significant contributions to the treatment of chronic lymphocytic leukemia (CLL) with recognized cardiovascular toxicities in some patients. This study aimed to assess the incidence of cardiotoxicity in CLL patients treated with ibrutinib and identify associated risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed 79 CLL patients treated with ibrutinib at the University Clinical Center of Serbia. Patient characteristics, treatment outcomes, and cardiovascular events were analyzed to determine the incidence of cardiotoxicity and its potential predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age at diagnosis was 58 years, with 63.3% male patients. Pre-existing cardiovascular conditions were present in 55.7% of patients. Cardiotoxicity occurred in 29.1% of patients, with atrial fibrilation developing in 10.1% patients (37.5% grade 3), leading to therapy discontinuation in 62.5% of those affected. Also, we diagnosed hypertension in 15.2%, heart failure in 7.6%, and myocardial infarction in 2.5% of patients. Furthermore, one case (1.3%) of sudden cardiac death was recorded. The administration of ibrutinib was ceased in 9 patients due to cardiotoxic effects. Patients with prior cardiovascular disease had a threefold increased risk of developing cardiotoxicity (HR=2.850; p=0.031). A history of hypertension was significantly associated withthe worsening of hypertension during ibrutinib therapy (HR=7.935; p=0.009). No significant associations were found between cardiotoxicity and other factors such as age, sex, number of prior treatment lines, clinical stage, or cytogenetic abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study underscores the importance of cardiovascular monitoring in CLL patients undergoing ibrutinib therapy, particularly those with pre-existing cardiovascular conditions. These findings highlight the need for individualized treatment planning and close follow-up to mitigate the risk of cardiotoxicity and optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1624761","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:26Z","timestamp":1756181606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Jelena","family":"Ivanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Otasevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojin","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Bibic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Tomic Vujovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofija","family":"Kozarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vladicic Masic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Milic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Kulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","unstructured":"Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl ComprCancNetw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.blre.2025.101268","article-title":"BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies","volume":"70","author":"Kozarac","year":"2025","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir T","year":"2019","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev OncolHematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.043","article-title":"The cardiologist and the cancer patient: challenges to cardio-oncology (or onco-cardiology) and call to action","volume":"272","author":"Okwuosa","year":"2018","journal-title":"J Am CollCardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"5103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1339874","article-title":"Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management","volume":"259","author":"Thorp","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00576-3","article-title":"Management of ibrutinib toxicities: a practical guide","volume":"315","author":"Lasica","year":"2020","journal-title":"CurrHematolMalig Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16326","article-title":"Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia","volume":"2","author":"Roeker","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011569","article-title":"Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study","volume":"8","author":"Samples","year":"2024","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2021-152167","article-title":"Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: analysis from the phase III NCRI FLAIR trial","volume":"138","author":"Munir","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.11.019","article-title":"Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials","volume":"5","author":"Alexandre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","author":"Ganatra","year":"2018","journal-title":"JACC: Clin Electrophysiology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in\u00a0patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"J Am Coll CardiolCardioOnc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardiooncology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: A population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40959-024-00237-x","article-title":"Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database","volume":"10","author":"Vallabhaneni","year":"2024","journal-title":"Cardiooncology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28589","article-title":"Bruton\u2019s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification","volume":"15","author":"Patel","year":"2024","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0421","article-title":"Genetic predictors of ibrutinib-related cardiovascular side effects in patients with chronic lymphocytic leukemia","volume":"29","author":"Hamadeh","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:28Z","timestamp":1756181608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":36,"alternative-id":["10.3389\/fonc.2025.1624761"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1624761","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1624761"}}